First patient treated with Clarity’s copper-64 SAR-Bombesin in breast cancer clinical trial

Clean Sweep Live Auction on Wed. Sept. 23rd. Click to see the full inventory

First patient treated with Clarity’s copper-64 SAR-Bombesin in breast cancer clinical trial

Press releases may be edited for formatting or style | July 30, 2020 Molecular Imaging
Sydney, Australia 28 July 2020 – Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce that the first patient has been treated in the C-BOBCAT study (Copper-64 BOmbesin in Breast CAncer Trial).

The C-BOBCAT trial is a first-in-human, investigator-led clinical trial investigating 64Cu-SAR-Bombesin (SAR-BBN) in patients with hormone receptor positive/HER2 negative (HR+/HER2-) metastatic breast cancer. The trial is led in collaboration with Associate Professor Louise Emmett, Director of Theranostics and Nuclear Medicine, at St Vincent’s Hospital in Sydney.

Bombesin is a natural homolog to the mammalian gastrin-releasing peptide, which is able to specifically bind to the gastrin-releasing peptide receptor (GRPr). GRPr is present on the membrane of most prostate, breast, ovarian and small cell lung cancers, gastrointestinal stromal tumours, and in tumoural vessels of urinary cancers. In relation to breast cancer, HR+/HER2- breast cancers make up roughly 67%1 of new breast cancer cases diagnosed each year, affecting roughly 181,000 women in 2019 in the USA2 alone, and approximately 13,000 women in Australia3.

Servicing GE/Siemens Nuclear Medicine equipment with OEM trained engineers

Numed, a well established company in business since 1975 provides a wide range of service options including time & material service, PM only contracts, full service contracts, labor only contracts & system relocation. Call 800 96 Numed for more info.

Clarity’s Executive Chairman, Dr Alan Taylor, said, “We are excited to commence this trial as SAR-BBN is Clarity’s second product after SARTATE™ to enter the clinical development stage. We are looking forward to progressing this study with our collaborators at St Vincent’s Hospital in Sydney, who have been involved in some pioneering radiopharmaceutical studies in recent times. We hope that SAR-BBN will allow for Positron Emission Tomography (PET) imaging and localisation of metastatic breast cancer lesions that express GRPr, and we look forward to utilising that data to progress SAR-BBN into other diagnostic and therapeutic trials in a range of cancers that express GRPr with our ultimate goal of better treating children and adults with cancer.”


About Clarity
Clarity is a personalised medicine company focused on the treatment of serious diseases. The Company is a leader in innovative radiopharmaceuticals, developing targeted therapies for the treatment of cancer and other serious diseases in adults and children.

You Must Be Logged In To Post A Comment